Pharmaceutical company Amanta Healthcare has filed its draft red herring prospectus (DRHP) with markets regulator Securities and Exchange Board of India (SEBI) to raise funds through an initial public offering (IPO).
The issue size will be up to 1,25,00,000 equity shares with a face value of $10 each, which will be published as a new edition.
Amanta’s objective is to raise funds to cover the capital expenditure required for civil construction works and the purchase of equipment, plant and machinery to establish a new manufacturing line for SteriPort in Hariyala, Kheda, Gujarat.
It also aims to secure funding for capital expenditure requirements for the purchase of equipment, plant and machinery to establish a new small volume parenteral (SVP) manufacturing line at the same location and for general corporate purposes.
Beeline Capital Advisors is the lead book-running manager, while Linktime frame is the registrar of the affair.
About the company
Amanta Healthcare Limited is a pharmaceutical company specialized in the development, manufacturing and marketing of sterile liquid products. Using aseptic blow-fill-seal (ABFS) and injection-stretch-blow molding (ISBM) technologies, Amanta produces parenteral solutions that offer rapid drug absorption for patients who cannot take oral medications.
Amanta manufactures large and small volume parenterals (LVP and SVP) in six therapeutic segments, including fluid therapy, ophthalmology and respiratory care, as well as medical devices. Amanta’s facilities in Gujarat comply with global GMP standards and the company exports its products to 19 countries, with 113 active international product registrations.
In addition to marketing over 45 generics in India through a network of 289 distributors, Amanta partners with pharmaceutical companies to manufacture products at scale. The company is led by a highly experienced management team, committed to innovation and ensuring the highest quality standards in healthcare.
Besides Amanta Healthcare, All Time Plastics, Scoda Tubes and Dev Accelerator (DevX) have also submitted their draft red herring prospectuses (DRHPs) to SEBI, in preparation for their IPOs.
Disclaimer:
The information contained in this post is for general information purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the post for any purpose.
We respect the intellectual property rights of content creators. If you are the owner of any material featured on our website and have concerns about its use, please contact us. We are committed to addressing any copyright issues promptly and will remove any material within 2 days of receiving a request from the rightful owner.